HA15 is primarily investigated for its potential in cancer therapy due to its ability to induce oxidative stress in tumor cells. It targets the heat shock protein HSP70, disrupting its protective function and leading to cancer cell death. This compound shows promise in overcoming resistance to conventional treatments, particularly in melanoma and other solid tumors. Research indicates HA15 can enhance the effectiveness of existing anticancer drugs when used in combination, making it a candidate for adjuvant therapy. Its application is currently limited to preclinical studies, focusing on understanding optimal dosing and delivery methods for future clinical use.